###begin article-title 0
TDP-43 Is Not a Common Cause of Sporadic Amyotrophic Lateral Sclerosis
###end article-title 0
###begin p 1
Conceived and designed the experiments: AS JH BT. Performed the experiments: BT JS RG. Analyzed the data: BT JS RG. Contributed reagents/materials/analysis tools: CC. Wrote the paper: AS JH BT RG.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 36 42 36 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 237 243 237 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
TAR DNA binding protein, encoded by TARDBP, was shown to be a central component of ubiquitin-positive, tau-negative inclusions in frontotemporal lobar degeneration (FTLD-U) and amyotrophic lateral sclerosis (ALS). Recently, mutations in TARDBP have been linked to familial and sporadic ALS.
###end p 3
###begin title 4
Methodology/Principal Findings
###end title 4
###begin p 5
###xml 49 55 49 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 716 722 716 722 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 307 312 <span type="species:ncbi:9606">Human</span>
To further examine the frequency of mutations in TARDBP in sporadic ALS, 279 ALS cases and 806 neurologically normal control individuals of European descent were screened for sequence variants, copy number variants, genetic and haplotype association with disease. An additional 173 African samples from the Human Gene Diversity Panel were sequenced as this population had the highest likelihood of finding changes. No mutations were found in the ALS cases. Several genetic variants were identified in controls, which were considered as non-pathogenic changes. Furthermore, pathogenic structural variants were not observed in the cases and there was no genetic or haplotype association with disease status across the TARDBP locus.
###end p 5
###begin title 6
Conclusions
###end title 6
###begin p 7
###xml 44 50 44 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
Our data indicate that genetic variation in TARDBP is not a common cause of sporadic ALS in North American.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 452 455 452 455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002450-Logroscino1">[1]</xref>
###xml 456 459 456 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002450-Chi1">[2]</xref>
###xml 564 567 564 567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002450-Rosen1">[3]</xref>
###xml 580 583 580 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002450-Puls1">[4]</xref>
###xml 583 586 583 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002450-Mnch1">[5]</xref>
###xml 594 597 594 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002450-Hadano1">[6]</xref>
###xml 609 612 609 612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002450-Chen1">[7]</xref>
###xml 647 650 647 650 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002450-Nishimura1">[8]</xref>
###xml 981 984 981 984 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002450-Schymick1">[9]</xref>
Amyotrophic lateral sclerosis (ALS, OMIM #105400) is a rare and devastating neurodegenerative disorder of unknown etiology characterized by rapidly progressive paralysis leading to death due to respiratory failure, typically within 3-5 years of symptom onset. Population-based epidemiological studies of the disease show that between 1.6% and 5.7% of cases are familial in nature, whereas the remaining 95% occur sporadically throughout the population [1],[2]. Various genes that cause familial ALS have been identified, including copper/zinc superoxide dismutase [3], dynactin 1 [4][5], alsin [6], senataxin [7], and vesicle-associated protein B [8]. In contrast to familial ALS, the genetics of the sporadic form are poorly understood and it is not known if sporadic ALS is monogenic (i.e., a single-gene disorder), polygenic (i.e., multiple interacting genes), multi-factorial (i.e., interacting genetic and environmental factors), or arises from some unknown non-genetic cause [9].
###end p 9
###begin p 10
###xml 151 155 151 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002450-Leigh1">[10]</xref>
###xml 195 201 195 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 296 300 296 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002450-Neumann1">[11]</xref>
###xml 301 305 301 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002450-Mackenzie1">[12]</xref>
###xml 306 310 306 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002450-Robertson1">[13]</xref>
###xml 436 440 436 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002450-Wang1">[14]</xref>
###xml 597 601 597 601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002450-Ou1">[15]</xref>
###xml 684 688 684 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002450-Buratti1">[16]</xref>
###xml 731 737 731 737 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 867 873 867 873 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 1018 1022 1018 1022 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002450-Sreedharan1">[17]</xref>
###xml 1079 1085 1079 1085 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 1392 1396 1392 1396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002450-Gitcho1">[18]</xref>
###xml 1524 1530 1524 1530 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 1696 1700 1696 1700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002450-Kabashi1">[19]</xref>
###xml 1813 1817 1813 1817 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002450-VanDeerlin1">[20]</xref>
###xml 536 571 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
###xml 1876 1884 <span type="species:ncbi:9606">patients</span>
The neuropathology of ALS is characterized by the abnormal accumulation of insoluble ubiquitin proteins in the cytoplasm of degenerating motor neurons [10]. Recently, TAR DNA-binding protein 43 (TARDBP, OMIM #605078) was recognized as a major constituent of these neuronal cytoplasmic inclusions [11],[12],[13]. TDP-43 protein is evolutionary conserved and its structure consists of a glycine-rich domain and two RNA recognition motifs [14]. The exact function of TDP-43 remains unclear, though it is known to bind DNA and RNA (such as human immunodeficiency virus type 1 TAR DNA sequence motifs) [15], and to be involved in the regulation of messenger RNA splicing and exon skipping [16]. Four studies have independently reported TARDBP mutations in familial forms of ALS displaying autosomal dominant inheritance and in sporadic ALS. An A315T mutation in exon 6 of TARDBP was reported to segregate with disease within a multi-generational ALS family and this sequence variant was not found in 1,505 control subjects [17]. In other study, a missense mutation M337V in exon 6 of TARDBP segregated with disease within an ALS family across two generations. In addition, two missense mutations (Q331K and G294A) were identified in two of 372 sporadic ALS cases screened for mutations (representing 0.5% of the total cohort). None of the three mutations were identified in 1,262 control subjects [18]. In a separate study of 200 individuals with ALS from France and Quebec, eight additional sequence variants were identified in TARDBP including the previously identified A315T missense mutation and A382T in small families and D169G, G287S, G348C, R361S, N390D and N390S in individual sporadic cases [19]. In the latest study, two additional missense mutations (G290A and G298S) were identified in familial ALS cases [20]. None of the sequence variants identified in sporadic ALS patients have been seen in more than one case.
###end p 10
###begin p 11
###xml 52 58 52 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 321 324 321 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002450-Schymick1">[9]</xref>
###xml 409 415 409 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 507 513 507 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 572 578 572 578 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 653 659 653 659 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDDP</italic>
###xml 308 313 <span type="species:ncbi:9606">human</span>
###xml 690 695 <span type="species:ncbi:9606">Human</span>
In this study, we undertook mutational screening of TARDBP in a cohort of 279 North American sporadic ALS cases and in a cohort of 806 ethnically-matched controls. The same case-control cohort had been previously genotyped using Illumina HumanHap550 BeadChips which assay over 550,000 tagged SNPs across the human genome [9]. This genotype data was analyzed to identify (a) genomic structural variants of the TARDBP locus relevant to the pathogenesis of sporadic ALS, (b) genetic association of SNPs within TARDBP with disease status, and (c) common haplotypes across the TARDBP locus that alter risk of motor neuron degeneration. Finally, we sequenced TARDDP in the African samples of the Human Gene Diversity Panel (n = 173) to examine genetic diversity of this gene in non-Caucasian populations.
###end p 11
###begin title 12
Materials and Methods
###end title 12
###begin title 13
ALS and control series
###end title 13
###begin p 14
###xml 130 134 130 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002450-Brooks1">[21]</xref>
###xml 155 158 <span type="species:ncbi:9606">men</span>
###xml 171 176 <span type="species:ncbi:9606">women</span>
###xml 252 260 <span type="species:ncbi:9606">patients</span>
###xml 297 305 <span type="species:ncbi:9606">patients</span>
###xml 345 353 <span type="species:ncbi:9606">patients</span>
###xml 408 416 <span type="species:ncbi:9606">patients</span>
The case cohort used in this study consisted of 279 white, non-Hispanic subjects diagnosed with probable or definite sporadic ALS [21]. Of these, 181 were men and 98 were women and the average age of symptom onset was 55 years (range, 19-82 years). 58 patients described bulbar-onset disease, 217 patients presented with spinal-onset disease, 2 patients had generalized symptoms at onset and the remaining 2 patients presented with respiratory symptoms. These samples are publicly available from the NINDS Neurogenetics Repository at the Coriell Institute for Medical Research, NJ, USA ().
###end p 14
###begin p 15
###xml 718 721 718 721 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002450-Schymick1">[9]</xref>
###xml 759 762 <span type="species:ncbi:9606">men</span>
###xml 771 776 <span type="species:ncbi:9606">women</span>
The control cohort comprised of 806 neurologically normal white, non-Hispanic individuals obtained from the same NINDS Neurogenetics repository. These samples are available as precompiled panels (NDPT002, NDPT006, NDPT009, NDPT019 to NDPT024). None of the control samples had a medical history of ALS, Alzheimer's disease, ataxia, autism, bipolar disorder, brain aneurysm, dementia, dystonia, or Parkinson's disease and none had any first-degree relative with a known primary neurological disorder. The control and case cohorts were drawn from the same ethnic origin (i.e. Caucasian) at different clinical sites throughout the United States, but the control samples were not matched by age or sex with the ALS samples [9]. The control cohort consisted of 335 men and 471 women and the mean age at sample collection was 59 years (range 15-95 years).
###end p 15
###begin p 16
###xml 109 113 109 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002450-Cann1">[22]</xref>
###xml 206 212 206 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 75 80 <span type="species:ncbi:9606">Human</span>
###xml 470 478 <span type="species:ncbi:9606">patients</span>
An additional series of 173 anonymous African samples that are part of the Human Gene Diversity Panel (HGDP) [22] were included in the mutational analysis as controls to evaluate the genetic variability of TARDBP in non-Caucasian populations. These samples originated from eight different African populations, namely Biaka Pygmy (n = 35), Mozabite (n = 26), Bedouin (n = 25), Mandenka (n = 24), Yoruba (n = 23), Bantu (n = 20), Mbuti Pygmy (n = 13) and San (n = 7). All patients and controls gave written informed consent to participate in the study.
###end p 16
###begin title 17
DNA Sequencing
###end title 17
###begin p 18
###xml 72 78 72 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
All the coding exons and 30bp of the flanking intron-exon boundaries of TARDBP (NM007375.3) were PCR amplified using primers designed using Primer3 software (available upon request) and Roche FastStart PCR MasterMix polymerase (Roche Diagnostics Corp., IN). Each PCR product was sequenced using Applied Biosystems BigDye terminator v3.1 sequencing chemistry and run on an ABI3730xl (Applied Biosystems, CA) genetic analyzer as per manufacturer's instructions. The sequences were analyzed with Sequencher software, version 4.2 (Genecodes, VA).
###end p 18
###begin title 19
SNP chip genotyping
###end title 19
###begin p 20
###xml 215 218 215 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002450-Schymick1">[9]</xref>
###xml 408 411 408 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002450-Schymick1">[9]</xref>
###xml 437 441 437 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002450-Fung1">[23]</xref>
###xml 703 706 703 706 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002450-Schymick1">[9]</xref>
###xml 708 712 708 712 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002450-Fung1">[23]</xref>
All 279 US ALS samples included in this study had been previously genotyped with Illumina Infinium II HumanHap550 SNP chips (Illumina, San Diego, CA, USA) as part of a whole genome association study of sporadic ALS [9]. DNA from 594 control subjects had also been genotyped using HumanHap550 SNP chips. The remaining 212 control individuals were assayed with both Illumina Infinium II HumanHap240S SNP chips [9] and HumanHap317 SNP chip [23] and the data from both these chips were combined to provide a final control genotyping dataset containing the same 555,000 SNPs as the cases. Raw genotype data for 258 of the ALS cases and 259 of the control samples have previously been made publicly available [9], [23].
###end p 20
###begin p 21
###xml 262 267 <span type="species:ncbi:9606">Human</span>
All samples were genotyped at the Laboratory of Neurogenetics, National Institute on Aging, Bethesda, MD according to the manufacturer's protocol. The resulting genotypes were visualized using the BeadStudio software package version 3.1.4 (Illumina, Inc.) using Human Genome Build 17 as reference. Any sample with a call rate below 95% were repeated on a fresh DNA aliquot and if the call rate persisted below this level the sample was excluded from the analysis.
###end p 21
###begin title 22
Copy number variant analysis
###end title 22
###begin p 23
###xml 347 353 347 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 684 686 684 686 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">th</sup>
###xml 741 744 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
Two metrics generated during SNP chip genotyping (namely, logR ratio which is a normalized value representing the total amount of DNA hybridized to a SNP probe, and B allele frequency which represents the fraction of intensity due to the B allele) were manually inspected to determine the number of allele copies at each SNP. Using this data, the TARDBP locus (plus the flanking 100kb) was evaluated for structural genomic variants. A two-tailed Fisher exact test (1 degree of freedom) was then used to evaluate the significance of differences between cases and controls at each SNP. Duplications and deletions were analyzed separately. The Database of Genomic Variants (, accessed 28th January 2008) was reviewed to determine if identified CNV had been previously described.
###end p 23
###begin title 24
Genetic and haplotype association analysis
###end title 24
###begin p 25
###xml 19 25 19 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 221 225 221 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002450-Purcell1">[24]</xref>
42 SNPs within the TARDBP locus and the flanking 100kb were genotyped by the Illumina HumanHap550 BeadChip and were available for analysis. SNP and haplotype association were computed for each SNP using the PLINK toolset [24]. Each SNP was required to have a call rate greater than or equal to 95% and each SNP was tested for departures from Hardy-Weinberg equilibrium. Association tests were computed using an additive model (Cochran-Armitage trend test, 1 degree of freedom), and using the three-marker sliding-window haplotype-association algorithm contained within PLINK. Odds ratios with upper and lower bound 95% confidence intervals were computed for the minor allele of each SNP.
###end p 25
###begin title 26
Results
###end title 26
###begin p 27
###xml 0 7 0 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002450-t001">Table 1</xref>
###xml 376 382 376 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
Table 1 details the sequence variants found in the 279 ALS cases, the 806 North American controls and in the 173 African samples that were screened as part of this study. Pathogenic mutations were not identified in any of the 279 ALS cases. Five of the ALS samples (ND09546, ND10023, ND09582, ND10379, ND10379) carried the synonymous variation p.A66A (c.198 T>C) in exon 2 of TARDBP, but this sequence variant was likely to be a benign polymorphism as it was found in eight of the Caucasian controls and in a single Bedouin sample of the HGDP. Furthermore, the previously reported pathogenic sequence variants were not present in any of the case or control samples, though a synonymous variant involving codon 315 (p.A315A, c.945G>A) was identified in a single Caucasian control individual (ND05681).
###end p 27
###begin title 28
###xml 33 39 33 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
Sequence variations found in the TARDBP gene in the 279 ALS cases, 806 North American controls and 173 African samples.
###end title 28
###begin p 29
###xml 280 286 280 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
Nineteen control samples were excluded due to poor quality genotyping on the Illumina HumanHap SNP chips (i.e. call rates <95%). Thus the final cohort for which genotyping chip data was available consisted of 279 ALS cases and 787 control individuals. Copy number analysis of the TARDBP locus using data generated with Illumina Infinium II HumanHap550 BeadChips did not reveal structural abnormalities affecting the TARDBP gene (+/-75kb) in any of the 279 cases.
###end p 29
###begin p 30
###xml 76 82 76 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 481 490 481 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002450.s001">Tables S1</xref>
###xml 495 497 495 497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002450.s002">S2</xref>
Statistical analysis of association was done for 42 tagging SNPs within the TARDBP gene and the flanking 100kb, irrespective of Hardy-Weinberg disequilibrium or minor allele frequency. One SNP (rs12059717 located 17.kb from the gene) was excluded due to low call rate. None of the remaining 41 SNPs were significantly associated with altered risk of developing ALS under the additive model. Similarly, no haplotype significantly altering disease risk was identified (Supplementary Tables S1 and S2).
###end p 30
###begin title 31
Discussion
###end title 31
###begin p 32
###xml 39 45 39 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 365 371 365 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 589 595 589 595 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 758 764 758 764 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 977 981 977 981 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002450-Tan1">[25]</xref>
###xml 982 986 982 986 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002450-Arai1">[27]</xref>
###xml 263 271 <span type="species:ncbi:9606">patients</span>
In this study we evaluated the role of TARDBP in the pathogenesis of sporadic ALS by undertaking sequence mutational analysis, as well as evaluating genomic structural variation, genetic association and haplotype association in a cohort of 279 North American ALS patients and 806 neurologically normal controls. We did not find any genetic or genomic evidence that TARDBP was associated with sporadic disease. Although the size of our cohort is not large enough to exclude this gene as the underlying etiology of occasional rare cases of sporadic ALS, our data indicates that mutations in TARDBP are not a common cause of sporadic motor neuron degeneration in the North American population (i.e. no greater than 0.4% of all cases). Although mutations in the TARDBP gene are rare, the protein may still play an important role in ALS. In fact, several studies have linked ALS pathogenesis to perturbations of TDP-43 nuclear trafficking, solubility and intracellular accumulation [25]-[27].
###end p 32
###begin p 33
###xml 71 76 71 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDP</italic>
###xml 110 114 110 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002450-Gijselinck1">[28]</xref>
###xml 1146 1150 1146 1150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002450-Kabashi1">[19]</xref>
###xml 101 109 <span type="species:ncbi:9606">patients</span>
Our data agree with previous reports of a negative association between TARDP and ALS in 237 sporadic patients [28]. Furthermore, we did not find any case or control samples in our series that carried any of the previously reported pathogenic mutations (A315T, A382T or M337V) that have been reported in familial cases, or any of the 8 variants (D169G, G287S, G294A, Q331K, G348C, R361S, N390D and N390S) that each have been reported in single sporadic cases. Although the published segregation data strongly supports the pathogenicity of the M337V and A315T mutations within these families, the lack of further examples of the eight mutations identified within sporadic ALS cases suggests that the true pathogenic nature of these variants remains to be established. Interestingly, all the variants found and considered by the authors as pathogenic, with the exception of D169G in exon 4, are situated in exon 6; all non-synonymous but benign variants identified by us, lie outside of this exon. These mutations may alter the normal function/transport of TDP-43 or they may cause a toxic gain of function of the protein by altering its C-terminal [19].
###end p 33
###begin p 34
###xml 27 33 27 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 372 378 372 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 480 486 480 486 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
Structural variants of the TARDBP gene were not a cause of sporadic ALS in our dataset. Although the density of SNPs on the Illumina HumanHap550 is not sufficient to exclude small deletions or insertions (42 SNPs over 212.9Kb, 1 SNP per 5Kb), our sequence analysis did excluded the presence of small deletions/insertions within the coding sequence and flanking introns of TARDBP. Finally, neither genetic association nor haplotype association with disease was observed across the TARDBP locus. Although this analysis was based on a relatively small number of markers, these 42 SNPs were tagging SNPs that are representative of neighboring sequence variation and extract a larger amount of genetic information than a similar number of randomly chosen SNPs.
###end p 34
###begin p 35
###xml 13 19 13 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 566 570 566 570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002450-Rosenberg1">[29]</xref>
###xml 572 576 572 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002450-Watkins1">[30]</xref>
###xml 641 647 641 647 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
We sequenced TARDBP in a cohort of 173 African samples to determine the variability of the gene in a non-Caucasian population and because this population carried the highest likelihood of finding changes. As expected, given the greater genetic variation known to exist within African populations, SNPs were more commonly present in this cohort compared to the Caucasian controls (6,9% compared to 1,1%). This observation is consistent with the older age of these populations with the consequent accumulation of sequence variants over a greater number of generations [29], [30]. Interestingly, we observed only two non-synonymous SNPs within TARDBP in both the African and Caucasian controls (i.e. D65E and A90V). We speculate that the biological importance of this gene has resulted in negative selective pressure against variants that alter TDP-43 amino-acid sequence.
###end p 35
###begin p 36
###xml 67 73 67 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 234 240 234 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 143 151 <span type="species:ncbi:9606">patients</span>
In conclusion, our comprehensive genetic and genomic assessment of TARDBP failed to identify disease associated variants in the North American patients studied here. Taken together with previous reports, we conclude that mutations in TARDBP are not a common cause of sporadic motor neuron degeneration.
###end p 36
###begin title 37
Supporting Information
###end title 37
###begin p 38
###xml 285 290 <span type="species:ncbi:9606">human</span>
Statistical analysis of association of the 41 tagging SNPs within the TARDBP gene and flanking 100kb and the risk of disease. None of the 41 tagging SNPs was significantly associated with an altered risk of developing ALS. CHR: Chromosome; bp position: base pairs position relative to human genome build 36; p<0.05 values were considered statistically significant.
###end p 38
###begin p 39
(0.10 MB DOC)
###end p 39
###begin p 40
Click here for additional data file.
###end p 40
###begin p 41
Statistical analysis of association of haplotypes within the TARDBP locus and the risk of disease. None of the haplotypes was significantly associated with an altered risk of developing ALS. p<0.05 values were considered statistically significant.
###end p 41
###begin p 42
(0.24 MB DOC)
###end p 42
###begin p 43
Click here for additional data file.
###end p 43
###begin title 44
References
###end title 44
###begin article-title 45
Incidence of amyotrophic lateral sclerosis in southern Italy: a population based study.
###end article-title 45
###begin article-title 46
Prevalence of SOD1 mutations in the Italian ALS population.
###end article-title 46
###begin article-title 47
Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis.
###end article-title 47
###begin article-title 48
Mutant dynactin in motor neuron disease.
###end article-title 48
###begin article-title 49
Point mutations of the p150 subunit of dynactin (DCTN1) gene ALS.
###end article-title 49
###begin article-title 50
A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2.
###end article-title 50
###begin article-title 51
DNA/RNA Helicase Gene Mutations in a Form of Juvenile Amyotrophic Lateral Sclerosis (ALS4).
###end article-title 51
###begin article-title 52
A Mutation in the Vesicle-Trafficking Protein VAPB Causes Late-Onset Spinal Muscular Atrophy and Amyotrophic Lateral Sclerosis.
###end article-title 52
###begin article-title 53
Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data.
###end article-title 53
###begin article-title 54
Ubiquitin-immunoreactive intraneuronal inclusions in amyotrophic lateral sclerosis. Morphology, distribution, and specificity.
###end article-title 54
###begin article-title 55
Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis.
###end article-title 55
###begin article-title 56
Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations.
###end article-title 56
###begin article-title 57
###xml 44 59 <span type="species:ncbi:10090">transgenic mice</span>
Lack of TDP-43 abnormalities in mutant SOD1 transgenic mice shows disparity with ALS.
###end article-title 57
###begin article-title 58
Structural diversity and functional implications of the eukaryotic TDP gene family.
###end article-title 58
###begin article-title 59
###xml 80 115 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs.
###end article-title 59
###begin article-title 60
TDP-43 binds heterogeneous nuclear ribonucleoprotein A/B through its C-terminal tail: an important region for the inhibition of cystic fibrosis transmembrane conductance regulator exon 9 splicing.
###end article-title 60
###begin article-title 61
TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis.
###end article-title 61
###begin article-title 62
TDP-43 A315T mutation in familial motor neuron disease.
###end article-title 62
###begin article-title 63
TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis.
###end article-title 63
###begin article-title 64
TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis.
###end article-title 64
###begin article-title 65
El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis.
###end article-title 65
###begin article-title 66
###xml 2 7 <span type="species:ncbi:9606">human</span>
A human genome diversity cell line panel.
###end article-title 66
###begin article-title 67
Genome-wide genotyping in Parkinson's disease and neurologically normal controls: first stage analysis and public release of data.
###end article-title 67
###begin article-title 68
PLINK: a tool set for whole-genome association and population-based linkage analyses.
###end article-title 68
###begin article-title 69
TDP-43 immunoreactivity in neuronal inclusions in familial amyotrophic lateral sclerosis with or without SOD1 gene mutation.
###end article-title 69
###begin article-title 70
Disturbance of nuclear and cytoplasmic Tar DNA binding protein (TDP-43) induces disease-like redistribution, sequestration and aggregate formation.
###end article-title 70
###begin article-title 71
TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis.
###end article-title 71
###begin article-title 72
Neuronal inclusion protein TDP-43 has no primary genetic role in FTD and ALS.
###end article-title 72
###begin article-title 73
###xml 21 26 <span type="species:ncbi:9606">human</span>
Genetic structure of human populations.
###end article-title 73
###begin article-title 74
Genetic variation among world populations: inferences from 100 Alu insertion polymorphisms.
###end article-title 74
###begin p 75
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 75
###begin p 76
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This study was supported by grants from the ALS Association, the Packard Center for ALS Research at Hopkins, the intramural programs of NIA (1 Z01 AG000951-06) and NINDS and grant #SFRH/BD/27442/2006 from Fundacao para a Ciencia e Tecnologia, Portugal. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 76

